Skip to main content

Advertisement

Advertisement

World

Novavax starts allowing participants on placebo to get COVID-19 vaccine in trials

Novavax starts allowing participants on placebo to get COVID-19 vaccine in trials

FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Novavax logo in this illustration taken on Feb 9, 2021. (Photo: REUTERS/Dado Ruvic)

MARYLAND: Novavax said on Monday (Apr 5) participants in its ongoing COVID-19 vaccine trials in South Africa and the UK can now receive additional shots, ensuring those who received a placebo can also get the active vaccine.

Allowing volunteers to crossover to the active vaccine offers them an incentive to continue in the trials even when other authorised vaccines are available.

The company said it planned to cross over participants in its ongoing large, late-stage study in the United States and Mexico, for which the company plans to read out initial clinical data during the second quarter.

READ: US may not need AstraZeneca COVID-19 vaccine: Anthony Fauci

READ: Serum Institute delays expected launch of Novavax vaccine in India

If authorised for emergency use in the United States, Novavax's two-shot vaccine would help ramp up ongoing vaccination efforts in the country with currently authorised vaccines from Pfizer/BioNTech, Moderna and Johnson & Johnson.

As part of the updated trial design, all participants of the trials in the UK and the US will be offered the chance to receive an additional round of shots, the company said.

Participants who opt to do so will receive two additional doses of either vaccine for those who initially received placebo, or placebo for those who first got vaccine.

All participants will continue to be "blinded" or not know if they got the experimental vaccine or a placebo.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram​​​​​​

Source: Reuters/ga

Advertisement

Also worth reading

Advertisement